Targeting KRAS: Promising New Therapy for Hard-to-Treat Lung …
3 days ago · Learn more Non-small cell lung cancer (NSCLC) became the proving ground for the first successful KRAS-targeted therapies with the FDA approval of sotorasib in 2021 and adagrasib in …
KRAS - Wikipedia
KRAS (Kirsten rat sarcoma virus oncogene homologue) is a gene that provides instructions for making a protein called K-Ras, a part of the RAS/MAPK pathway. The protein relays signals from outside the …
What’s new in KRAS mutation research? - MD Anderson Cancer Center
The most frequently mutated of these oncogenic driver genes, called KRAS, is associated with some of the most fatal cancer types: lung, pancreatic and colorectal cancers.
KRAS mutated lung adenocarcinoma responds to pan-ERBB and
6 days ago · KRAS mutations are prevalent in lung adenocarcinoma (LUAD). Although KRAS-targeted therapies such as KRAS-G12C inhibitor sotorasib are now clinically available, their durability is …
Zoldonrasib Earns FDA Breakthrough Therapy Status in KRAS G12D …
Jan 9, 2026 · The FDA designates zoldonrasib as a breakthrough therapy for KRAS G12D-mutated lung cancer, highlighting its promising efficacy and safety profile.
KRAS and Lung Cancer - American Lung Association
Dec 2, 2025 · The KRAS gene normally acts as a communication hub for signals that lead to cell growth. When a mutation occurs, KRAS send too many signals, causing uncontrolled cell growth and leading …
KRAS Mutations in Solid Tumors: Characteristics, Current Therapeutic ...
Kristen rat sarcoma (KRAS) gene is one of the most common mutated oncogenes in solid tumors. Yet, KRAS inhibitors did not follow suit with the development of targeted therapy, for the structure of …
Zoldonrasib Earns FDA Breakthrough Therapy Designation in KRAS …
Jan 9, 2026 · The FDA has granted breakthrough therapy designation to zoldonrasib (RMC-9805), an investigational RAS (ON) KRAS G12D inhibitor, as a treatment for adults with locally advanced or …
Zoldonrasib Nets Breakthrough Therapy Designation in KRAS …
Jan 8, 2026 · Zoldonrasib has received breakthrough therapy designation in pretreated KRAS G12D-mutated locally advanced or metastatic NSCLC.
Novel drug combination overcomes resistance in aggressive KRAS …
5 days ago · A research team at the Medical University of Vienna has discovered a new approach to treating a particularly frequent and difficult-to-treat form of lung cancer.